ADC Therapeutics (ADCT) announced the completion of enrollment in LOTIS-5, the Phase 3 confirmatory trial evaluating Zynlonta in combination with rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma. Zynlonta previously received accelerated approval for the treatment of r/r DLBCL after two or more lines of systemic therapy from the FDA in 2021.
Don't Miss Our New Year's Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ADCT:
- ADC Therapeutics falls -8.9%
- ADC Therapeutics announces data from LOTIS-7 Phase 1b open-label clinical trial
- ADC Therapeutics: Updated data from Phase 2 Zynlonta study published in Lancet
- Molson Coors upgraded, Rivian downgraded: Wall Street’s top analyst calls
- ADC Therapeutics Highlights Q3 Advances and Strategic Focus